View Older Stories View More Recent Stories
-
Roth Capital Trims PT on Yingli Green Energy (YGE) to $1.30 Following Q1 Report
-
Atossa Genetics (ATOS) Announces $6.22 Common Stock, Warrants Direct Placement
-
Atossa Genetics Inc. to Raise Approximately $6,220,000 From Institutional Healthcare Investors
-
Roth Capital Raised Price Target Following Ligand Pharma (LGND) Receipt of Milestone Payment
-
Roth Capital Downgrades Zumiez, Inc. (ZUMZ) to Neutral
-
Positive FDA Committee Vote on Flibanserin Bodes Well for Palatin's (PTN) Bremelanotide - Roth Capital
-
Roth Capital Starts Mad Catz Interactive (MCZ) at Buy
-
Notable Analyst Rating Changes 6/4: (CAVM) (T) (FTR) Upgraded; (TWTR) (DDS) (VZ) Downgraded
-
Roth Capital Maintains Buy Rating on Pixelworks (PXLW) Following Asus Design Win
-
Roth Capital Starts Coeur d'Alene Mines (CDE) at Buy
-
Sky-mobi Announces Appointment of New Independent Director
-
Detwiler Fenton Group Adds Investment Banking
-
Roth Capital Assumes Dot Hill (HILL) at Buy
-
Celator Pharmaceuticals (CPXX) Phase III Induction CR/CRi Data 'Major Catalyst', Roth Capital Says
-
Notable Mergers and Acquisitions 6/3: (STCK) (URRE) (BABA)
-
Uranium Resources (URRE), Anatolia Energy to Merge
-
Uranium Resources and Anatolia Energy Announce Merger with Aim to Fast-Track Uranium Production
-
Roth Capital Cuts Price Target on ReneSola (SOL) Following Q1 Miss and Weak Guidance
-
Roth Capital Maintains Buy on Power Solutions (PSIX) Following a Revised Outlook
-
ReneSola (SOL) Plans to Wind Down OEM Operations; Roth Affirms at 'Neutral' Following Q1 Results, Outlook
-
Roth Capital Maintains Bullish View on uniQure BV (QURE) Ahead of Data; Sees as Potential Takeout Candidate
-
Roth 'Encouraged' by Progress in Phase II GANNET53; Reaffirms Synta (SNTA) at 'Buy'
-
Notable 52-Week Highs and Lows 6/2: (ETFC) (RXDX) (AER) High; (OGE) (CZR) Low
-
Notable Analyst Rating Changes 6/2: (GFI) (ZION) (BUD) Upgraded; (ALTR) (IRM) (ITC) Downgraded
-
Pre-Open Stock Movers 06/02: (AVEO) (VICL) (TA) Higher; (SOL) (TUBE) (RGLS) Lower (more...)
-
Roth Capital Starts Cogentix Medical (CGNT) at Neutral
-
Roth Capital Remains Bullish on Curis (CRIS) Following '907 Presentation at ASCO
-
Roth Capital Starts Vical (VICL) at Buy; $4.65 PT
-
Roth Capital Starts Evolution Petroleum (EPM) at Buy
-
Roth Affirms Vascular Biogenics (VBLT) at 'Buy' Following VB-111 in rGBM Update; Phase 3 Study is 'Well Designed'
-
Roth Capital Reiterates Buy on Pacific Ethanol (PEIX) Following Proposed Ethanol RVOs
-
CTI BioPharma (CTIB) Pacritinib a Real Threat to Ruxolitinib, Roth Capital Says
-
Roth Capital Bullish on Green Plains (GPRE) Following Proposed Ethanol RVOs
-
Power Solutions International to Present at Upcoming Investor Conferences
-
Power Solutions International to Present at Upcoming Investor Conferences
-
Strong Volumes Help JinkoSolar (JKS) in Q1; Next Catalysts Include Power Spin, FIT Payments - Roth Capital
-
Roth Capital Reiterates Buy on Revolution Lighting (RVLT) Expecting a 2Q Rebound
-
Claims Administrator Angeion Group Announces Proposed Settlement In China-Biotics Class Action
-
Roth Capital Downgrades Rally Software (RALY) to Neutral on Takeover; Look at (CTCT) (LPSN) (TNGO) to Replace
-
NV5 Announces Closing of Underwritten Public Offering of Common Stock
-
Notable Analyst Rating Changes 5/28: (RL) (JCI) (GM) Upgraded; (BT) (BONT) (TFM) Downgraded
-
Pre-Open Stock Movers 05/28: (RALY) (BIOC) (EXPR) Higher; (NBS) (DANG) (TLYS) Lower (more...)
-
Roth Capital Starts Digital Ally (DGLY) at Buy
-
Hydrogenics' (HYGS) Agreement with Alstom Seen as 'Milestone' for Fuel Cell Industry by Roth Capital
-
Wave Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
-
Roth Affirms bluebird bio (BLUE) at 'Buy'; Getting More Aggressive in Immuno-Onocology Sans Celgene (CELG)
-
Roth Capital Lifts FY15 Gross Margin, EPS Outlooks on Sky Solar (SKYS) Following Q1 Results, Maintained Guidance
-
Unusual 11 Mid-Day Movers 5/26: (GKNT) (ATNM) (FXCM) Higher; (CYRN) (JMEI) (GMAN) Lower
-
Streetinsider.com's Hot Lunchtime Reads 5/22: (DGX) (AAPL) (AWR) (DE)
-
Roth Capital 'Encouraged' by Latest GALE-401 Phase 2 Data; Affirms 'Buy' Rating on Galena Biopharma (GALE)

